What is CyGenica?
CyGenica is at the forefront of developing innovative delivery solutions for critical therapeutic components. The company leverages a proprietary non-viral, non-toxic platform designed for both in vitro and in vivo applications. This advanced technology is engineered to facilitate the precise delivery of drugs, gene editing tools, and antibiotics, addressing key challenges in modern medicine and offering a safer alternative to existing methods. The company's focus on a non-toxic approach positions it as a promising player in the biopharmaceutical delivery systems market.
How much funding has CyGenica raised?
CyGenica has raised a total of $1.4M across 1 funding round:
Angel/Seed
$1.4M
Angel/Seed (2021): $1.4M with participation from SOSV, David Rowan, Sharaf Yamani, Sami Mikati, and VOYAGER Health-Tech
Key Investors in CyGenica
SOSV
SOSV is a multi-stage venture capital investor known for providing both intellectual and financial capital to accelerate the growth of innovative companies.
David Rowan
David Rowan is an individual investor participating in the funding round, likely bringing expertise in technology and innovation.
Sharaf Yamani
Sharaf Yamani is an individual investor contributing to CyGenica's funding, indicating support for the company's technological advancements.
What's next for CyGenica?
With the infusion of major strategic investment, CyGenica is poised for accelerated development and market penetration. This substantial capital injection, contributing to the overall $1.4M, suggests the company is entering a scaling phase, likely focusing on expanding its research and development capabilities, advancing its platform through clinical trials, and potentially forging strategic partnerships. The enterprise-level nature of the funding indicates a strong belief in CyGenica's long-term vision and its capacity to disrupt the delivery solutions landscape.
See full CyGenica company page
